ADC Therapeutics(ADCT) - 2024 Q2 - Quarterly Results

Exhibit 99.1 ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024 LOTIS-7 trial enrollment on track with efficacy and safety data on eligible patients expected by year-end 2024 and mature data on all patients expected in first half of 2025 Full enrollment in LOTIS-5 trial expected before year-end 2024 Company to host conference call today at 8:30 a.m. EDT Lau ...